9/20/2025

There is a "for sale" sign on the sector, and these two stocks look particularly attractive at their current levels.

Source: Yahoo

9/19/2025

Pfizer and Arvinas plan to out-license their partnered drug vepdegestrant. Elsewhere, Novo shared more data for oral Wegovy and Vertex reached a deal in Italy for coverage of its gene editing medicine Casgevy.

Source: Yahoo

9/18/2025

LONDON, September 18, 2025--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with the Italian Medicines Agency (AIFA) for eligible transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel).

Source: Yahoo

9/17/2025

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $387.15, denoting a -1.08% move from the preceding trading day.

Source: Yahoo

9/17/2025

Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors

Source: MarketWatch

9/17/2025

Look beyond the recent headwinds these two have faced.

Source: Yahoo

9/17/2025

Vertex shares fall nearly 24% in six months on pipeline setbacks but strong CF sales and new launches may shape the future.

Source: Yahoo

9/17/2025

If you have been eyeing Vertex Pharmaceuticals and wondering whether it is the right time to buy, sell, or simply hold tight, you are far from alone. Vertex has been on a journey, sometimes up, sometimes down, which has kept investors on their toes. Over the past year, the stock fell 18.7%, a move that might make some skittish, while longer-term holders can still point to impressive gains of 36.4% over three years and 46.3% over five. Shorter-term numbers, like the -1.3% seven-day return and...

Source: Yahoo

9/15/2025

Fred Alger Management, LLC ("Alger"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index ("Index"). Following the close of trading on Friday, September 19, 2025, the Index will be rebalanced, and the following changes will be effective.

Source: Yahoo

9/15/2025

Here's why you can't find a Wall Street analyst who will tell you to sell this stock.

Source: Yahoo

9/13/2025

Vertex Pharmaceuticals is backed by CF dominance and JOURNAVX optionality, with key catalysts ahead for growth and upside. See why VRTX stock is a buy.

Source: SeekingAlpha

9/12/2025

Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Source: Yahoo

9/11/2025

Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains

Source: MarketWatch

9/11/2025

BOSTON, September 11, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named as one of the winners of this year’s Lasker~DeBakey Clinical Medical Research Award for his role "in the development of a novel, life-saving treatment for cystic fibrosis (CF) — namely, a triple-drug combination therapy, TRIKAFTA®, that has helped countless people with this genetic disease." Dr. Negulescu is one of three awardees, alongside Jesús

Source: Yahoo

9/10/2025

PIF’s US 13F portfolio value declined to $23.81B, with Uber, Electronic Arts, Lucid, Take-Two, and ARM comprising 77% of assets. See more insights here.

Source: SeekingAlpha

9/10/2025

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $388.55, marking a -2% move from the previous day.

Source: Yahoo

9/10/2025

The United States Cystic Fibrosis Therapeutics Market is set to grow from an estimated US$ 2.32 billion in 2024 to US$ 4.72 billion by 2033, with an 8.22% CAGR from 2025 to 2033. This growth is driven by advancements in gene therapy, increased access to CFTR modulators, and robust research initiatives. Key players like Vertex Pharmaceuticals and Abbvie leverage developments like Trikafta, expanding the therapeutic market. Challenges including high treatment costs and limited rural access persist

Source: Yahoo

9/9/2025

Get insights from Vertex Pharmaceuticals at the Morgan Stanley Global Healthcare

Source: SeekingAlpha

9/8/2025

Vertex Pharmaceuticals has lagged the broader S&P 500 Index over the past year, but Wall Street analysts remain moderately optimistic about the company’s long-term prospects.

Source: Yahoo

9/4/2025

Recent developments aren't as devastating to the company's prospects as some might think.

Source: Yahoo